April 28, 2022 -- Mission Bio CEO Yan Zhang, PhD, and associate director of business development (cell and gene therapies) Nori Ueno spoke with ScienceBoard.net at the Cell & Gene Meeting on the Med in Barcelona, Spain, about the company's recent accomplishments with Tapestri, Mission Bio's single-cell platform for DNA analysis.
Earlier this year, Mission Bio completed their first technology transfer of a cell and gene therapy assay to Avance Biosciences. The goal was to translate Mission Bio's work to a good manufacturing practice (GMP) environment, supporting the firms' shared partners in clinical trials.
"As a company, we're very proud of what we can do as part of the ecosystem to support our partners in their success," Zhang said.
"The platform is very uniquely suited for a better understanding of the heterogeneity behind drug resistance for cancer. And now we're playing a super important role in supporting cell and gene therapy."
Watch the video below to learn more.